Krystof S Bankiewicz

Author PubWeight™ 83.45‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Adeno-associated virus serotype 9 transduction in the central nervous system of nonhuman primates. Hum Gene Ther 2012 2.42
2 Image-guided convection-enhanced delivery platform in the treatment of neurological diseases. Neurotherapeutics 2008 1.79
3 Gadolinium-loaded liposomes allow for real-time magnetic resonance imaging of convection-enhanced delivery in the primate brain. Exp Neurol 2005 1.78
4 A dose-ranging study of AAV-hAADC therapy in Parkinsonian monkeys. Mol Ther 2006 1.77
5 Real-time visualization and characterization of liposomal delivery into the monkey brain by magnetic resonance imaging. Brain Res Brain Res Protoc 2005 1.74
6 Long-term evaluation of a phase 1 study of AADC gene therapy for Parkinson's disease. Hum Gene Ther 2012 1.70
7 Efficient gene therapy-based method for the delivery of therapeutics to primate cortex. Proc Natl Acad Sci U S A 2009 1.70
8 An engineered zinc finger protein activator of the endogenous glial cell line-derived neurotrophic factor gene provides functional neuroprotection in a rat model of Parkinson's disease. J Neurosci 2010 1.59
9 Transduction of nonhuman primate brain with adeno-associated virus serotype 1: vector trafficking and immune response. Hum Gene Ther 2009 1.55
10 Cerebral infusion of AAV9 vector-encoding non-self proteins can elicit cell-mediated immune responses. Mol Ther 2012 1.55
11 Real-time MR imaging of adeno-associated viral vector delivery to the primate brain. Neuroimage 2008 1.53
12 Strong cortical and spinal cord transduction after AAV7 and AAV9 delivery into the cerebrospinal fluid of nonhuman primates. Hum Gene Ther 2013 1.52
13 Interventional MRI-guided putaminal delivery of AAV2-GDNF for a planned clinical trial in Parkinson's disease. Mol Ther 2011 1.50
14 Safety evaluation of AAV2-GDNF gene transfer into the dopaminergic nigrostriatal pathway in aged and parkinsonian rhesus monkeys. Hum Gene Ther 2009 1.46
15 Biodistribution of adeno-associated virus type-2 in nonhuman primates after convection-enhanced delivery to brain. Mol Ther 2008 1.40
16 Novel nanoliposomal CPT-11 infused by convection-enhanced delivery in intracranial tumors: pharmacology and efficacy. Cancer Res 2006 1.36
17 Functional effects of AAV2-GDNF on the dopaminergic nigrostriatal pathway in parkinsonian rhesus monkeys. Hum Gene Ther 2009 1.36
18 Striatal volume differences between non-human and human primates. J Neurosci Methods 2008 1.33
19 Anterograde axonal transport of AAV2-GDNF in rat basal ganglia. Mol Ther 2010 1.32
20 Effects of the perivascular space on convection-enhanced delivery of liposomes in primate putamen. Exp Neurol 2005 1.32
21 Eight years of clinical improvement in MPTP-lesioned primates after gene therapy with AAV2-hAADC. Mol Ther 2010 1.31
22 Novel platform for MRI-guided convection-enhanced delivery of therapeutics: preclinical validation in nonhuman primate brain. Stereotact Funct Neurosurg 2011 1.30
23 Convection-enhanced delivery of Ls-TPT enables an effective, continuous, low-dose chemotherapy against malignant glioma xenograft model. Neuro Oncol 2006 1.29
24 Convection-enhanced delivery of a topoisomerase I inhibitor (nanoliposomal topotecan) and a topoisomerase II inhibitor (pegylated liposomal doxorubicin) in intracranial brain tumor xenografts. Neuro Oncol 2006 1.26
25 Convection-enhanced delivery of tumor necrosis factor-related apoptosis-inducing ligand with systemic administration of temozolomide prolongs survival in an intracranial glioblastoma xenograft model. Cancer Res 2004 1.26
26 Canine model of convection-enhanced delivery of liposomes containing CPT-11 monitored with real-time magnetic resonance imaging: laboratory investigation. J Neurosurg 2008 1.25
27 Optimized cannula design and placement for convection-enhanced delivery in rat striatum. J Neurosci Methods 2009 1.25
28 Optimal region of the putamen for image-guided convection-enhanced delivery of therapeutics in human and non-human primates. Neuroimage 2009 1.24
29 Real-time imaging and quantification of brain delivery of liposomes. Pharm Res 2006 1.22
30 Clinically relevant effects of convection-enhanced delivery of AAV2-GDNF on the dopaminergic nigrostriatal pathway in aged rhesus monkeys. Hum Gene Ther 2009 1.21
31 Convection-enhanced delivery of nanoliposomal CPT-11 (irinotecan) and PEGylated liposomal doxorubicin (Doxil) in rodent intracranial brain tumor xenografts. Neuro Oncol 2007 1.21
32 Tissue affinity of the infusate affects the distribution volume during convection-enhanced delivery into rodent brains: implications for local drug delivery. J Neurosci Methods 2006 1.17
33 Regeneration of the MPTP-lesioned dopaminergic system after convection-enhanced delivery of AAV2-GDNF. J Neurosci 2010 1.14
34 Safety of real-time convection-enhanced delivery of liposomes to primate brain: a long-term retrospective. Exp Neurol 2007 1.14
35 Real-time MR imaging with Gadoteridol predicts distribution of transgenes after convection-enhanced delivery of AAV2 vectors. Mol Ther 2010 1.09
36 Translational fidelity of intrathecal delivery of self-complementary AAV9-survival motor neuron 1 for spinal muscular atrophy. Hum Gene Ther 2014 1.08
37 Comparison of intratumoral bolus injection and convection-enhanced delivery of radiolabeled antitenascin monoclonal antibodies. Neurosurg Focus 2006 1.06
38 An α-synuclein AAV gene silencing vector ameliorates a behavioral deficit in a rat model of Parkinson's disease, but displays toxicity in dopamine neurons. Brain Res 2011 1.05
39 Qualitative imaging of adeno-associated virus serotype 2-human aromatic L-amino acid decarboxylase gene therapy in a phase I study for the treatment of Parkinson disease. Neurosurgery 2010 1.05
40 The PTEN/Akt pathway dictates the direct alphaVbeta3-dependent growth-inhibitory action of an active fragment of tumstatin in glioma cells in vitro and in vivo. Cancer Res 2006 1.04
41 AAV9: over the fence and into the woods . . . Mol Ther 2011 1.04
42 Image-guided convection-enhanced delivery of GDNF protein into monkey putamen. Neuroimage 2010 1.02
43 Safety and tolerability of magnetic resonance imaging-guided convection-enhanced delivery of AAV2-hAADC with a novel delivery platform in nonhuman primate striatum. Hum Gene Ther 2012 1.02
44 Cannula placement for effective convection-enhanced delivery in the nonhuman primate thalamus and brainstem: implications for clinical delivery of therapeutics. J Neurosurg 2010 0.99
45 Canine spontaneous glioma: a translational model system for convection-enhanced delivery. Neuro Oncol 2010 0.97
46 Convection-enhanced delivery of liposomes to primate brain. Methods Enzymol 2009 0.96
47 T2 imaging in monitoring of intraparenchymal real-time convection-enhanced delivery. Neurosurgery 2011 0.93
48 Glial-derived neurotrophic factor gene transfer for Parkinson's disease: anterograde distribution of AAV2 vectors in the primate brain. Neurobiol Dis 2011 0.93
49 Controlled dissemination of AAV vectors in the primate brain. Prog Brain Res 2009 0.93
50 Design of an in-dwelling cannula for convection-enhanced delivery. J Neurosci Methods 2010 0.93
51 Non-PEGylated liposomes for convection-enhanced delivery of topotecan and gadodiamide in malignant glioma: initial experience. J Neurooncol 2009 0.90
52 Gene and cell delivery to the degenerated striatum: status of preclinical efforts in primate models. Neurosurgery 2008 0.90
53 Transduction of antigen-presenting cells in the brain by AAV9 warrants caution in preclinical studies. Mol Ther 2015 0.90
54 Safety study of adeno-associated virus serotype 2-mediated human acid sphingomyelinase expression in the nonhuman primate brain. Hum Gene Ther 2012 0.89
55 Gene therapy for Parkinson's disease: from non-human primates to humans. Curr Opin Mol Ther 2010 0.88
56 PET 6-[F]fluoro-L-m-tyrosine Studies of Dopaminergic Function in Human and Nonhuman Primates. Front Hum Neurosci 2008 0.88
57 Ultrasound-enhanced drug transport and distribution in the brain. AAPS PharmSciTech 2010 0.86
58 Advances in thin tissue Golgi-Cox impregnation: fast, reliable methods for multi-assay analyses in rodent and non-human primate brain. J Neurosci Methods 2013 0.85
59 Merits of combination cortical, subcortical, and cerebellar injections for the treatment of Niemann-Pick disease type A. Mol Ther 2012 0.84
60 Gene therapy for Parkinson's disease: where are we now and where are we going? Expert Rev Neurother 2010 0.84
61 The use of convection-enhanced delivery with liposomal toxins in neurooncology. Toxins (Basel) 2011 0.83
62 Analysis of a simulation algorithm for direct brain drug delivery. Neuroimage 2011 0.83
63 Anatomic compression caused by high-volume convection-enhanced delivery to the brain. Neurosurgery 2009 0.82
64 Pharmacokinetics and bioactivity of glial cell line-derived factor (GDNF) and neurturin (NTN) infused into the rat brain. Neuropharmacology 2010 0.81
65 Evaluation of an AAV2-based rapamycin-regulated glial cell line-derived neurotrophic factor (GDNF) expression vector system. PLoS One 2011 0.80
66 Gene therapy for misfolding protein diseases of the central nervous system. Neurotherapeutics 2013 0.77
67 Automated segmentation tool for brain infusions. PLoS One 2013 0.77
68 Evaluation of pressure-driven brain infusions in nonhuman primates by intra-operative 7 Tesla MRI. J Magn Reson Imaging 2012 0.77
69 Gene therapy for the treatment of Parkinson's disease: the nature of the biologics expands the future indications. Pharmaceuticals (Basel) 2012 0.77
70 Human/nonhuman primate AC-PC ratio--considerations for translational brain measurements. J Neurosci Methods 2010 0.76
71 Pharmacokinetics, tumor accumulation and antitumor activity of nanoliposomal irinotecan following systemic treatment of intracranial tumors. Nanomedicine (Lond) 2014 0.76
72 Rapid inverse planning for pressure-driven drug infusions in the brain. PLoS One 2013 0.76
73 Systemic rapamycin alone may not be a treatment option for malignant glioma: evidence from an in vivo study. J Neurooncol 2012 0.75